First real-world use of new protocol for P. vivax case management in Brazil – a Health Ministry and MMV collaboration 08 Oct 2021
New Partnership launched to accelerate elimination of relapsing P. vivax malaria that poses a risk to an estimated 2.5 billion people worldwide 14 Jul 2021
STANDARD G6PD Test receives regulatory approval by the Australian Therapeutic Goods Administration 25 May 2021
GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration 08 Jan 2021
GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age 19 Nov 2020
Event Highlights from the VivAccess Hosted Symposium at Virtual ASTMH: Accelerating New Tools for Radical Cure of Vivax Malaria from Clinical and Operational Research to Policy 18 Nov 2020
Thailand becomes first malaria-endemic country in Asia-Pacific to approve tafenoquine for radical cure of P. vivax malaria 24 Apr 2020
05 Apr 2022 8th International Conference on Plasmodium vivax Research (ICPvR) 2022 The 8th International Conference on Plasmodium vivax Research will take place virtually from 5th - 8th April 2022. Deadline for abstract submissions: 12th January 2022. 5th - 8th April 2022 Global virtual event
